43.13
-2.27 (-4.99%)
| 前收盘价格 | 45.40 |
| 收盘价格 | 45.01 |
| 成交量 | 2,389,833 |
| 平均成交量 (3个月) | 1,477,550 |
| 市值 | 3,874,721,792 |
| 预期市盈率 (P/E Forward) | 23.36 |
| 价格/销量 (P/S) | 18.15 |
| 股市价格/股市净资产 (P/B) | 1.93 |
| 52周波幅 | |
| 利润日期 | 17 Feb 2025 - 3 Mar 2025 |
| 营业毛利率 | -118.13% |
| 营业利益率 (TTM) | -18,294.02% |
| 稀释每股收益 (EPS TTM) | -2.79 |
| 季度收入增长率 (YOY) | -99.30% |
| 总债务/股东权益 (D/E MRQ) | 11.73% |
| 流动比率 (MRQ) | 21.64 |
| 营业现金流 (OCF TTM) | -188.82 M |
| 杠杆自由现金流 (LFCF TTM) | -118.57 M |
| 资产报酬率 (ROA TTM) | -9.57% |
| 股东权益报酬率 (ROE TTM) | -13.07% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | CRISPR Therapeutics AG | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.38 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 1.69% |
| 机构持股比例 | 83.82% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 94.00 (Chardan Capital, 117.92%) | 购买 |
| 中 | 84.00 (94.74%) | |
| 低 | 53.00 (RBC Capital, 22.87%) | 保留 |
| 平均值 | 74.40 (72.48%) | |
| 总计 | 3 购买, 2 保留 | |
| 平均价格@调整类型 | 48.16 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JMP Securities | 20 Dec 2024 | 86.00 (99.37%) | 购买 | 39.95 |
| Chardan Capital | 10 Dec 2024 | 94.00 (117.92%) | 购买 | 48.68 |
| Barclays | 06 Nov 2024 | 55.00 (27.51%) | 保留 | 50.72 |
| Needham | 06 Nov 2024 | 84.00 (94.74%) | 购买 | 50.72 |
| RBC Capital | 06 Nov 2024 | 53.00 (22.87%) | 保留 | 50.72 |
| 04 Oct 2024 | 53.00 (22.87%) | 保留 | 45.37 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合